Lumateperone (Caplyta) for Schizophrenia
Date: July 27, 2020
Issue #:
1603Summary:
The FDA has approved lumateperone (Caplyta—
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Abilify Abilify MyCite Antipsychotics Aripiprazole Asenapine brexpiprazole Caplyta cariprazine Clozapine Clozaril Geodon iloperadine Invega Latuda lumateperone lurasidone Olanzapine paliperidone Quetiapine Rexulti R Source Type: research
More News: Abilify | Drugs & Pharmacology | Geodon | Invega | Schizophrenia | Seroquel | Ziprasidone | Zyprexa